Stratos Wealth Advisors LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Stratos Wealth Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 35.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,949 shares of the biopharmaceutical company's stock after purchasing an additional 18,900 shares during the period. Stratos Wealth Advisors LLC's holdings in Pfizer were worth $1,823,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Starboard Value LP purchased a new stake in shares of Pfizer in the fourth quarter valued at $407,730,000. Assenagon Asset Management S.A. grew its position in shares of Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after purchasing an additional 7,581,030 shares during the period. Massachusetts Financial Services Co. MA grew its position in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. grew its position in Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after acquiring an additional 5,153,257 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PFE shares. Morgan Stanley boosted their price target on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Bank of America boosted their price target on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Finally, BMO Capital Markets lowered their price target on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $28.55.

Pfizer Trading Up 1.5%

Shares of PFE opened at $25.61 on Wednesday. The company has a market capitalization of $145.60 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock has a 50-day moving average price of $23.80 and a 200 day moving average price of $24.81.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.82 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.72%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.